IL-2-loaded liposomes modified with sorafenib derivative exert a synergistic anti-melanoma effect via improving tumor immune microenvironment and enhancing antiangiogenic activity

Immunotherapy with interleukin-2 (IL-2) in treating cancers is subject to several limitations such as systemic side effects and reduced efficacy against tumors with low immune cell infiltration despite its promise. To address these challenges, IL-2-So-Lipo, a novel liposomal formulation combining IL...

Full description

Bibliographic Details

Published in:	Asian Journal of Pharmaceutical Sciences
Main Authors:	Xuan Huang, Kudelaidi Kuerban, Jajun Fan, Danjie Pan, Huaning Chen, Jiayang Liu, Songna Wang, Dianwen Ju, Yi Zhun Zhu, Jiyong Liu, Li Ye
Format:	Article
Language:	English
Published:	Elsevier 2025-04-01
Subjects:	Melanoma Il-2 liposome Sorafenib Tumor immunotherapy Synergistic immunotherapy Nanoliposome
Online Access:	http://www.sciencedirect.com/science/article/pii/S1818087625000066